US FDA approves Takeda, Protagonist's drug for rare blood cancer

The FDA approved a first-of-its-kind drug from Takeda Pharmaceutical and Protagonist Therapeutics to treat a rare blood cancer. The approval is a significant regulatory milestone likely to improve near-term expectations for the companies’ oncology pipeline and commercialization prospects, with potential modest positive read-through to their fundamentals.